Arsenictrioxide Accord Arsenictrioxide Accord | European Medicines Agency (EMA)Skip to main contentSearchMain navigation * Medicines * Find medicine * Therapeutic areas: latest updates * Download medicine data * What we publish on medicines and when * Medicines under evaluation * National registers * Human regulatory * Overview * Research and development * Marketing authorisation * Post * Glossaries * About this website * Data protection and privacy * Contacts 1. Home 2. Medicines 3. Arsenictrioxide Accord Arsenictrioxide AccordRSSAuthorisedThis medicine is authorised for use in the European Union arsenic trioxideMedicineHumanAuthorised Page contents * Overview * Product information * Product details * Authorisation details * Assessment history * News on Arsenictrioxide Accord * More
Arsenictrioxide for promyelocytic leukaemia Prepared by the All Wales Therapeutics and Toxicology Centre Page 1 of 5 Arsenictrioxide in combination with all-trans retinoic acid for the first-line treatment of high-risk acute promyelocytic leukaemia in adult patients unsuitable for anthracycline-based therapy (OW06) September 2023 ONE WALES INTERIM DECISION Arsenictrioxide Government Arsenictrioxide in combination with all-trans retinoic acid can be made available within NHS Wales for the first line treatment of high-risk acute promyelocytic leukaemia, characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha gene, in adult patients unsuitable for anthracycline-based therapy. The risks
Arsenictrioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over) NHS England » Arsenictrioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over) Skip to main content Cookies on the NHS England websiteWe’ve put some small files called * Publications * Statistics * Blogs * Events * Contact us Search Search Menu * About us * Our work * Commissioning * Get involved Arsenictrioxide in combination with all-trans retinoic acid for the treatment of high-risk acute promyelocytic leukaemia (age 12 months and over)Document first published: 27 February 2025 Page updated: 27 February 2025 Topic: Specialised commissioning Publication type: Policy
Sodium arsenite and arsenictrioxide differently affect the oxidative stress of lymphoblastoid cells: An intricate crosstalk between mitochondria, autophagy and cell death. Although the toxicity of arsenic depends on its chemical forms, few studies have taken into account the ambiguous phenomenon that sodium arsenite (NaAsO2) acts as a potent carcinogen while arsenictrioxide (ATO, As2O3) serves
Salvage chemotherapy regimens with arsenictrioxide for relapsed or refractory neuroblastoma: a promising approach. In patients with relapsed or refractory neuroblastoma (NB), the limited efficacy of conventional chemotherapies necessitates the exploration of new treatment options. Previous studies have highlighted the anti-tumor properties of arsenictrioxide (ATO) in high-risk NB (HR-NB
Targeting Nrf2/HO-1 signaling by crocin: Role in attenuation of arsenictrioxide-induced neurotoxicity in mice. Saffron is a valued herb, obtained from the stigmas of the C.sativus Linn (Iridaceae). Pharmacopoeias have described it as having a variety of actions, such as stimulant, anti-carcinogen, and anti-depressant. As a folk medicine, crocin has been reported to have anti-cardiotoxicity and anti-hepatotoxicity effects. This paper focuses on crocin, one of the bioactive molecules found in saffron that are known to have therapeutic effects. Crocin has been shown in numerous experimental studies to be beneficial in treating depression, however, there aren't many studies on its neurotoxicity. Applications of arsenictrioxide (ATO) in medical settings is limited by its side effects
[Short-term results of a multicenter study based on a modified N7 induction regimen combined with arsenictrioxide in the treatment of children with high-risk neuroblastoma]. To analyze the short-term clinical efficacy and safety of arsenictrioxide (ATO) combined with a modified N7 induction regimen in the treatment of children with high-risk neuroblastoma (NB). This study was a prospective
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenictrioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. All-trans retinoic acid (ATRA) and arsenictrioxide (ATO) combinations have produced excellent outcomes in patients with standard-risk acute promyelocytic leukemia (APL). Herein, the authors update their long-term results with the regimen of ATO-ATRA
Low-dose arsenictrioxide inhibits pancreatic stellate cell activation via LOXL3 expression to enhance immunotherapy in pancreatic cancer. Pancreatic cancer (PC) is characterized by abnormally fibrotic mesenchyme, which notably influences on the effectiveness of immunotherapy. Low-dose arsenictrioxide (ATO, 1.0 μM) can inhibit the activation of pancreatic stellate cells (PSCs) and affect
Arsenictrioxide versus Realgar-Indigo naturalis formula in non-high-risk acute promyelocytic leukemia: a multicenter, randomized trial. Realgar-Indigo Naturalis Formula (RIF) is an oral form of arsenic that is effective against acute promyelocytic leukemia (APL). This multicenter, randomized, controlled trial compared the efficacy of all-trans retinoic acid (ATRA) plus RIF with ATRA plus arsenictrioxide (ATO) in a simplified regimen for non-high-risk APL. Following induction therapy with ATRA and ATO, participants were randomly assigned to receive either ATRA plus ATO or ATRA plus RIF both in a 2-week on 2-week off schedule for consolidation therapy. Once achieving molecular complete remission, the regimen was administered for a total of 6 cycles. All of 108 eligible patients achieved
Arsenictrioxide (Trisenox) - for the induction of remission, and consolidation in adult patients with newly diagnosed, low-to-intermediate risk acute promyelocytic leukaemia (APL) 1 Published 14 January 2019 1 SMC2025 arsenictrioxide 1mg/mL concentrate for solution for infusion (Trisenox®) Teva UK Ltd 7 December 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission assessed under the orphan equivalent process arsenictrioxide (Trisenox®) is not recommended for use within NHSScotland. Indication under review: in combination with all-trans-retinoic acid
Arsenictrioxide (Trisenox) - acute promyelocytic leukaemia (APL) 1 Published 8 July 2019 1 SMC2181 arsenictrioxide 1mg/mL concentrate for solution for infusion (Trisenox®) Teva UK Ltd 7 June 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a resubmission arsenictrioxide (Trisenox®) is accepted for use within NHSScotland. Indication under review: in combination with all-trans-retinoic acid (ATRA [tretinoin]) for the induction of remission, and consolidation in adult patients with newly diagnosed, low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood
Transcatheter arterial chemoembolization using CalliSpheres beads loaded with arsenictrioxide for unresectable large or huge hepatocellular carcinoma: a prospective study. To determine the safety and efficacy of transcatheter arterial chemoembolization with CalliSpheres® beads loaded with arsenictrioxide (CBATO-TACE) in the first-line treatment of patients with large (5 cm ≤ maximum diameter with arsenictrioxide (CBATO-TACE) were effective and safe for the treatment of large and giant HCC. In addition, CBATO-TACE can reduce lateral hepatic branch artery formation and extrahepatic pulmonary metastasis, which provides a new treatment approach for unresectable HCC. • We compare long-term efficacy and safety of transcatheter arterial chemoembolization with CalliSpheres® beads loaded with arsenic
Assessment of ArsenicTrioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial. All-trans retinoic acid (ATRA) and arsenictrioxide therapy without the use of maintenance therapy has been found to be beneficial for the treatment of adults with standard-risk acute promyelocytic leukemia (APL ). However, it is unclear whether similar regimens are safe and beneficial for the treatment of high-risk APL or pediatric patients with standard-risk APL. To assess whether treatment with an ATRA and arsenictrioxide-based regimen is safe and allows for the elimination or substantial reduction of chemotherapy use among pediatric patients with standard-risk or high-risk APL, respectively. The Children's
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenictrioxide for acute promyelocytic leukemia in all risk groups (APL15 trial). The combination of all-trans retinoic acid (ATRA) and arsenictrioxide (ATO) has been demonstrated to have comparable effectiveness or better to ATRA and chemotherapy (CHT) in non-high-risk acute promyelocytic leukemia (APL). However
A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenictrioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical. Cervical cancer is the fourth most common malignancy in women, which is threatening female reproductive tract health. Chemotherapy can be used for neoadjuvant therapy of locally
Arsenictrioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. Boosting tumor immunosurveillance with vaccines has been proven to be a feasible and cost-effective strategy to fight cancer. Although major breakthroughs have been achieved in preventative tumor vaccines targeting oncogenic viruses, limited advances have been made in curative vaccines for virus-irrelevant malignancies. Accumulating evidence suggests that preconditioning tumor cells with certain cytotoxic drugs can generate whole-cell tumor vaccines with strong prophylactic activities. However, the immunogenicity of these vaccines is not sufficient to restrain the outgrowth of existing tumors. In this study, we identified arsenictrioxide (ATO) as a wide-spectrum